Let’s Meet to Discuss Your Next Study
Schedule a meeting to learn more about why biotech sponsors have been choosing PSI CRO for their pivotal Phase 2 and 3 trials for more than 25 years.
Senior Director, Business Development
Mobile: +33 (671) 114 934
Focused & specialized global CRO
PSI is the global leader in radioligand research, running 50% of the industry’s pivotal Phase 2 and 3 radiopharm studies. We work with more than 1,000 experienced sites worldwide and have a dedicated regulatory team that continues to maintain and grow our knowledge to speed up country and site activation.
Clinical trial sponsors working in oncology, hematology, IBD, infectious diseases, multiple sclerosis, and many rare diseases around the world rely on PSI’s guidance and experience, knowing we’re specialized and committed to delivering some of the most complex clinical projects in the industry.
Read our latest resource
Operationalizing Radiopharmaceutical Clinical Trials: Opportunities & Challenges
Success starts with understanding the risk factors that can impact your radiopharmaceutical trial from startup through the clinical phase.